

# MYELOPROLIFERATIVE NEOPLASMS: THE CHALLENGES, SUCCESSES AND STRATEGIES FOR 2012

A CME symposium at the 6th International  
Congress on Myeloproliferative Diseases  
and Myelodysplastic Syndromes

Thursday, November 3, 2011




New York Marriott at the  
Brooklyn Bridge Hotel

333 Adams Street  
Brooklyn, NY 11201

Salon A-D

Wine & Cheese Reception: 5:30 pm

Symposium: 6:00 pm – 8:30 pm



## Chairmen:

**Jerry L. Spivak, MD, FACP**

Sidney Kimmel Comprehensive Cancer Center  
Johns Hopkins University School of Medicine  
Baltimore, MD

**Richard T. Silver, MD, FACP**

Weill Cornell Medical College  
New York-Presbyterian Hospital/  
New York, NY

## Faculty:

**Tiziano Barbui, MD**

Ospedali Riuniti di Bergamo  
Bergamo, Italy

**John Goldman, DM, FRCP**

Hammersmith Hospital  
Imperial College London  
London, United Kingdom

**Srdan Verstovsek, MD, PhD**

The University of Texas  
M. D. Anderson Cancer Center  
Houston, Texas

## Agenda

5:30pm – 6:00pm

**Welcome reception and registration**

6:00pm

**Introduction from the chairs:** *Dr Richard Silver and Dr Jerry Spivak*

6:00pm – 6:30pm

**Primary myelofibrosis (PMF):**

Dr Verstovsek will discuss the pertinent biological and clinical issues, and the emerging role (and challenges) of JAK2 inhibitors and other novel agents for patients with myelofibrosis. He will illustrate this with a case presentation.

6:30pm – 7:00pm

**Polycythemia vera (PV)**

Dr Spivak will review the clinical significance of mutations, clinical features and the management of patients with PV followed by a case presentation.

7:00pm – 7:30pm

**Essential thrombocythemia (ET)**

Dr Barbui will discuss the impact of recent molecular and therapeutic advances on how we diagnose and manage patients with ET followed by a case presentation.

7:30pm – 8:00pm

**Chronic myeloid leukemia (CML)**

Dr Goldman will address how patients with CML have been served remarkably well by advances in cellular and molecular biology and the speed at which these findings were translated to improving treatment. He will then present a case-based treatment algorithm.

8:00pm – 8:30pm

**Panel discussion**

**Chairs:** *Richard Silver & Jerry Spivak*

**Panelists:** *Srdan Verstovsek, John Goldman, Tiziano Barbui*

8:30pm

**Adjourn**

## Program Overview

Over the past two decades, we have witnessed some of the most dramatic advances in understanding the biology and development of new therapies in hematologic malignancies. For 'classic' myeloproliferative neoplasms (MPN), this has resulted in the introduction of tyrosine kinase inhibitors (TKIs) for patients with CML which has improved the overall 10-year survival. More recently, several JAK-2 inhibitors have been tested in patients with MF, and current evidence suggests, that though they might not eradicate the malignant clone, they provide clinically significant benefits. This inaugural CME-certified symposium will offer up-to-date information relevant to our research and clinical practice in MPN. For many patients with MPN, given that the current clinical management is often minimally effective, this should be of interest to all medical professionals in this field.

## Target Audience

This activity has been designed to meet the medical educational needs of hematologists, oncologists, and other healthcare professionals involved in the care of patients with all myeloproliferative neoplasms (MPN).

## Educational Objectives

After completing this activity, the participant should be better able to:

- Discuss cellular and molecular biology of MPN including the relevance of the somatic mutations such as *JAK2*, *MPL*, *LNK* and others
- Compare the novel prognostic classifications for patients with MPN
- Contrast the significance of JAK2 allelic burden in JAK2 positive MPN
- Review the risk factors for thrombosis, including the leukemic transformation in MPN
- Outline recent clinical trial data for candidate JAK-2 inhibitors and other novel agents in clinical trials for the treatment of MPN, including SAR302503, CYT387, CEP701, ruxolitinib and others
- Outline novel agents in clinical trials in MPN: panobinostat, pomalidomide, mTOR inhibitors, pegylated interferon alfa and others
- Review the clinical management of patients with CML, in particular, current and future generation TKIs
- Appraise the treatment of T315I CML subclone
- Evaluate updated management guidelines for patients with MPN

## Physician Continuing Education

### Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and Alpine Oncology. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

### Credit Designation

The Postgraduate Institute of Medicine designates this live activity for a maximum of 2.5 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

## Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.